At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 37 enrolled
Drug / intervention
LY2140023drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating LY2140023 for Hepatic Insufficiency. Completed, enrolled 37 participants across 2 sites in 2 countries.
Detailed Summary
This study will explore how liver impairment affects blood levels of LY2140023 (a prodrug) and its active metabolite (LY404039).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Insufficiency
CountriesGermany, Hungary
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedNov 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedNov 21, 2011
Enrollment StartNov 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.6 years ago
Interventions
LY2140023drug